Med. praxi. 2011;8(3):130-133 [Interní Med. 2010; 12(10): 516-519]

Is metformin only an antidiabetic drug?

prof.MUDr.Jindřiška Perušičová, DrSc.
Interní klinika FN Motol a 2. LF UK Praha

For over fifty years, metformin has been known as an effective antihyperglycaemic drug not associated with weight gain. In recent years,

it has been successfully used in nondiabetic situations as well. Metformin substitutes for the lack of safe anti-obesity medications, is the

drug of choice in women with PCOS and is therapeutically valid in individuals with NASH. The most significant activity of metformin that

has been shown recently is its anti-tumorous effect in a number of cancers.

Keywords: metformin, weight, PCOS, NASH, oncological therapy

Published: March 23, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Perušičová J. Is metformin only an antidiabetic drug? Med. praxi. 2011;8(3):130-133.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Green BD, Irwin N, Duffy NA, et al. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol. 2006; 10, 547(1-3): 192-199. Go to original source... Go to PubMed...
    2. Charles MA, Morange P, Eschwege E, et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the Bigpro1 study. Biguanides and the prevention of the risk of obesity. Diabetes Care 1998; 21(11): 1967-1972. Go to original source... Go to PubMed...
    3. Charles MA, Eschw?ge E, Grandmottet P, et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev. 2000; 16(1): 2-7. Go to original source... Go to PubMed...
    4. Bard JM, Charles MA, Juhan-Vague I, et al. Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. Arterioscler Thromb Vasc Biol. 2001; 21(3): 407-414. Go to original source... Go to PubMed...
    5. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother. 2008; 42(6): 817-826. Go to original source... Go to PubMed...
    6. Golay A. Metformin and body weight. International Journal of Obesity, 2008; 32: 61-72. Go to original source... Go to PubMed...
    7. Lim S, Norman R, Clifton P, Noakes M. The effect of comprehensive lifestyle intervention or metformin on obesity in young women. Nutr Metab Cardiovasc Dis. 2010; Feb 15. [Epub ahead of print]. Go to original source... Go to PubMed...
    8. Ibá?ez L, Lopez-Bermejo A, Diaz M, et al. Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity. J Pediatr. 2010; 156(1): 98-102. Go to original source... Go to PubMed...
    9. Rogovik AL, Chanoine JP, Goldman RD. Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity. Drugs 2010; 12, 70(3): 335-346. Go to original source... Go to PubMed...
    10. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001; 50(12): 1457-1461. Go to original source... Go to PubMed...
    11. Paulweber B, Valensi P, Lindström J, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010; 42(Suppl 1): S3-36. Go to original source... Go to PubMed...
    12. Otta CF, Wior M, Iraci GS, et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol Endocrinol. 2010; 26(3): 173-178. Go to original source... Go to PubMed...
    13. Cibula D, Stárka L, Vrbíková J. Syndrom polycystických ovarií. Praha: Maxdorf, 2004.
    14. Duvnjak M, Tomasic V, Gomercic M, et al. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol. 2009; 60(Suppl 7): 57-66.
    15. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther. 2009; 26(10): 893-907. Go to original source... Go to PubMed...
    16. Lilly M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009; 55(4): 363-369. Go to PubMed...
    17. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes (ZODIAC-16). Diabetes Care 2009 Nov 16. [Epub ahead of print]. Go to original source... Go to PubMed...
    18. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305. Go to original source... Go to PubMed...
    19. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32(9): 1620-1625. Go to original source... Go to PubMed...
    20. Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008; 8(6): 501-505. Go to original source... Go to PubMed...
    21. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 1, 8(13): 2031-2040. Go to original source... Go to PubMed...
    22. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 2009; 18(3): 701-705. Go to original source... Go to PubMed...
    23. Rattan R, Giri S, Hartmann L, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2009 Oct 29. [Epub ahead of print]. Go to original source... Go to PubMed...
    24. Wang LW, Li ZS, Zou DW, et al. Metformin induces apoptosis of pancreatic cancer cells. J Gastroenterol. 2008; 21, 14(47): 7192-7198. Go to original source... Go to PubMed...
    25. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa). 2008; 1(5): 369-375. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.